Federal contract award
75A50124C00061
PARTNER THERAPEUTICS: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO CONFIRM LEUKINE SAFETY IN SEPSIS PATIENTS, INFORM OPTIMAL LEUKINE DOSING, EXPLORE LEUKINE EFFICACY, AS WELL AS ADVANCE DEVELOPMENT OF MONOCYTE HUMAN LEUKOCYTE ANTIGEN-DR (MHLA-DR) AS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $13.0M |
| Current contract value | $13.0M |
| Potential contract value / ceiling | $13.7M |
| Start date | Sep 30, 2024 |
| Current end date | Mar 31, 2028 |
| Potential end date | Sep 30, 2028 |
| Latest award activity | Aug 8, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 4 of 4 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 8, 2025 | P00003 | $0 | THE PURPOSE OF THIS NO COST MODIFICATION IS TO UPDATE SECTION G.1 CONTRACTING OFFICER FROM REBECCA FOSTER TO AUDREY GLOVER. |
| May 7, 2025 | P00002 | $0 | PARTNER THERAPEUTICS: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO CONFIRM LEUKINE SAFETY IN SEPSIS PATIENTS, INFORM OPTIMAL LEUKINE DOSING, EXPLORE LEUKINE EFFICACY, AS WELL AS ADVANCE DEVELOPMENT OF MONOCYTE HUMAN LEUKOCYTE ANTIGEN-DR (MHLA-DR) AS |
| Feb 28, 2025 | P00001 | $0 | PARTNER THERAPEUTICS: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO CONFIRM LEUKINE SAFETY IN SEPSIS PATIENTS, INFORM OPTIMAL LEUKINE DOSING, EXPLORE LEUKINE EFFICACY, AS WELL AS ADVANCE DEVELOPMENT OF MONOCYTE HUMAN LEUKOCYTE ANTIGEN-DR (MHLA-DR) AS |
| Sep 24, 2024 | 0 | $13.0M | PARTNER THERAPEUTICS: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO CONFIRM LEUKINE SAFETY IN SEPSIS PATIENTS, INFORM OPTIMAL LEUKINE DOSING, EXPLORE LEUKINE EFFICACY, AS WELL AS ADVANCE DEVELOPMENT OF MONOCYTE HUMAN LEUKOCYTE ANTIGEN-DR (MHLA-DR) AS |
Estimated positioning window
Sep 30, 2027 – Mar 30, 2028
65/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 65/100. Available recorded signals: 60 points.
- Contract end 2028-09-30 (699 days from calculation)
- +25 points
- 18 historical awards in this buyer and category group
- +15 points
- 4 recorded award transactions
- +10 points
- Latest award action: 2025-08-08
- +0 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.